BCOP Prep Course (BCOP): free quiz

1. Question 1 of 10

   A pharmacist reviews pembrolizumab 200 mg IV every 3 weeks for metastatic non-small cell lung cancer with high PD-L1 expression and no targetable driver alteration on molecular testing. Which tumor-biology concept best explains why an anti-PD-1 strategy may be beneficial in this setting?

   Choose one answer

   ATumor cells acquire genomic instability solely to increase sensitivity to cytotoxic chemotherapy, making checkpoint inhibition secondarily effective.BTumor cells metastasize because EGFR signaling is universally activated, so PD-1 blockade mainly works by inhibiting receptor tyrosine kinase signaling.CTumor cells primarily depend on VEGF-mediated angiogenesis, so blocking immune checkpoints directly suppresses endothelial proliferation.DTumor cells evade immune destruction by exploiting PD-1/PD-L1 signaling, which dampens T-cell activity in the tumor microenvironment.
2. Question 2 of 10

   An oncology pharmacist is prioritizing same-day review of several new treatment starts. Which patient factor from the selected topic most directly supports urgent pharmacist attention?

   Choose one answer

   AA high tumor burden with a rapid proliferative rateBA cancer type label without any consideration of kinetics or burdenCA low-burden malignancy with no treatment schedule considerationsDA regimen in which timing is assumed to be clinically irrelevant
3. Question 3 of 10

   A tumor board case describes progression after a targeted regimen. The tumor still depends on growth signaling, but the original inhibited pathway is no longer the only route maintaining malignant behavior. Which mechanism is most consistent with this scenario?

   Choose one answer

   ABypass signalingBDrug effluxCRepair pathway activationDTreatment pressure absence
4. Question 4 of 10

   A pharmacist is reviewing a proposed targeted therapy. The report clearly identifies a point mutation, but the treatment plan does not state the tumor type or assay validity. What is the best interpretation?

   Choose one answer

   AThe point mutation classification is useful, but actionability still requires tumor and assay contextBAny point mutation is automatically actionable in every tumor typeCA point mutation should be treated as an amplification if targeted therapy is orderedDAssay validity is irrelevant when the alteration is a point mutation
5. Question 5 of 10

   Which statement best summarizes why NGS assay limits are tested in a BCOP-style QBank?

   Choose one answer

   AThey affect how confidently a pharmacist can verify biomarker-directed targeted therapy.BThey determine whether a pharmacist can independently perform tumor biopsy procedures.CThey replace the need for oncology testing and biomarker interpretation.DThey are relevant only to laboratory billing and not to patient management.
6. Question 6 of 10

   A BCOP-style item stem provides details indicating that a patient is not in an average-risk screening group. What should the examinee do with that information?

   Choose one answer

   ADisregard it because risk categories are not part of the selected topic.BUse it to distinguish the appropriate screening framework described in the stem.CAssume the same counseling point applies to every patient regardless of risk context.DConvert the question into a pharmacogenomics question because risk status always implies genotype testing.
7. Question 7 of 10

   A patient says, "I found a supplement online that claims to prevent cancer. Can you approve this as my prevention plan?" Based on the selected source pack, which pharmacist response is most appropriate?

   Choose one answer

   AApprove the supplement as a complete cancer prevention plan.BRedirect the conversation to guideline-based risk-reduction counseling and referral rather than endorsing unsupported prevention claims.CTell the patient that cancer prevention counseling is never appropriate in oncology pharmacy.DDiagnose the patient's hereditary risk status before discussing prevention.
8. Question 8 of 10

   Which pharmacist action most directly supports the blueprint area of patient and caregiver education within therapeutic implementation?

   Choose one answer

   AAssess whether the patient and caregiver understand instructions and can access credible support resourcesBSelect an investigational drug endpoint for a phase 2 studyCDetermine the exact mutation type from sequencing outputDDevelop a hazardous medication disposal policy
9. Question 9 of 10

   A patient is eligible for a biomarker-directed therapy in the current disease setting. The pharmacist notes that the patient previously received a regimen with substantial cumulative toxicity affecting the same organ system that the new regimen may worsen. Which concept best explains why this history matters for later-line selection?

   Choose one answer

   ABiomarker status and cumulative toxicity can alter later-line optionsBCumulative toxicity is only relevant during first-line treatmentCBiomarker status replaces the need to review prior exposureDLater-line options are determined only by patient preference
10. Question 10 of 10

    A prescriber enters an oncology regimen with an abbreviated schedule. The pharmacist cannot determine whether the schedule is based on an approved protocol, a local pathway, or an intentional individualized adjustment. Which action best supports safe verification?

    Choose one answer

    AVerify as entered because abbreviated schedules never need protocol support.BClarify the intended schedule and protocol basis with the care team.CAssume the schedule is incorrect and cancel all orders.DAsk nursing to decide whether the schedule is acceptable at administration.

Check my answers